Friday, October 10, 2014. 6:00 AM - 7:45 AM at the Hynes Convention Center, Boston, MA. Room 210.
Please note: Registration to AMCP Nexus 2014 is required in order to attend this satellite symposium.
Hot Topics Include:
- Assessment of Evolving Guidelines and Evidence-Base of HCV Treatments
- Therapeutic Recommendations for Various HCV Patient Types
- Pharmacy Benefit Design Innovations for a New Era of HCV Management
- HCV Specialty Pharmacy Services and Disease Management Strategies for Managed Care Pharmacy
Who Should Attend?
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of AMCP, and other managed health care professionals attending AMCP Nexus 2014.
Statement of Need/Program Overview
With the current availability and potential approval of additional protease inhibitors (PIs) for hepatitis C virus (HCV), managed care organization (MCO) decision makers must consider many factors as they develop appropriate management strategies and tactics: drug costs, patient management needs, adherence, comparative safety and efficacy, and appropriate utilization management controls. Although PIs offer significant advancements in HCV care, appropriate utilization management strategies are critical for MCOs focused on enduring that HCV patients receive optimal benefit from these therapies.
Educational Objectives
After completing this activity, the participant should be better able to:
- Apply evidence-based treatment strategies to optimize outcomes for patients with HCV within a managed care setting
- Cite recently updated American Association for the Study of Liver Disease (AASLD), Infectious Diseases Society of America (IDSA), and the American College of Gastroenterology (ACG) treatment guidelines on current and emerging treatment options for HCV, including efficacy, safety, and tolerability
- Recommend benefit design that takes into account patient out-of-pocket expenses (OOP) to remove barriers and improve adherence and overall value for the management of HCV
- Evaluate pharmacy management strategies, including specialty pharmacy services and disease management, that MCOs can implement to improve overall patient outcomes for HCV patients
- Provide accurate and appropriate counsel as part of the managed care treatment team
Distinguished Faculty Presenters
|
Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC |
|
Nancy S. Reau, MD Associate Professor of Medicine Staff Physician of Medicine The University of Chicago Medicine |
Date and Time
Friday, October 10, 2014
6:00 AM - 7:45 AM
Hynes Convention Center
Room 210
Boston, MA
Agenda
| 6:00 AM | Breakfast and Registration |
| 6:15 AM |
Opening: Introduction/Objectives/Pre-Activity Assessment |
| 6:20 AM |
Assessment of Evolving Guidelines and Evidence-Base of HCV Treatments |
| 6:35 AM |
Therapeutic Recommendations for Various HCV Patient Types |
| 6:55 AM |
Pharmacy Benefit Design Innovations for a New Era of HCV Management |
| 7:10 AM | HCV Specialty Pharmacy Services and Disease Management Strategies for Managed Care Pharmacy |
| 7:30 AM | Faculty Discussion Session |
| 7:45 AM | Evaluation and Post-Activity Survey |
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 |
Pharmacist Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-14-209-L01-P)
For Pharmacists: Upon receipt of a completed activity evaluation form, you will receive an email from Postgraduate Institute for Medicine with a link and directions to submit your credit to NABP CPE Monitor Services.
Type of Activity: Application
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.
Fee Information
No additional fee is required to attend this CPE/CME activity.
Note: There is NO FEE for attending this Satellite Symposium. However, if you wish to attend the AMCP Nexus 2014 sessions from October 7th through October 10th, a registration fee is required.
Pre-registration will close at 12:00 pm on October 8, 2014.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.